← Leaderboards
Christopher Austin Klebanoff
Sloan-Kettering Inst Can Research
$3,971,923
Attributed
$3,971,923
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,971,923 · 2
By mechanism
R37$2,596,206 · 1
R01$1,375,717 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Jennifer Cf Leng$9,013,476
- Triparna Sen$3,760,270
- Katharine C Hsu$29,362,365
- Tao Dao$540,804
- Prasad S. Adusumilli$7,809,681
Others in their field
Other Emerging Leaders on “Mutation”
- Leonard Freedman · Leidos Biomedical Research, Inc.$85,874,322
- John Damon Chodera · Sloan-Kettering Inst Can Research$48,421,310
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$38,744,543
- Lynn Briscoe · Leidos Biomedical Research, Inc.$38,032,945
- Maria C Carrillo · Indiana University Indianapolis$19,445,642
- James Dale Berry · Brigham And Women'S Hospital$19,118,191
Research focus
MutationMultidisciplinaryMutateImmunotherapyMolecularComplexInnovationGene TherapyImmuneImmunogenicityMass Spectrum AnalysisMediatingAntigensAffinityAllelesCancer PatientFrequenciesCancer CellBindingHla AntigensImmunogenicBiometryMalignant NeoplasmsNeoantigens
Grant awards (8)
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.$521,188
R37 · FY2025 · CA · contact PI
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma$438,385
R01 · FY2025 · CA · contact PI
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.$492,199
R37 · FY2024 · CA · contact PI
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma$430,781
R01 · FY2024 · CA · contact PI
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.$518,107
R37 · FY2023 · CA · contact PI
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma$506,551
R01 · FY2023 · CA · contact PI
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.$527,065
R37 · FY2022 · CA · contact PI
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.$537,647
R37 · FY2021 · CA · contact PI